Serum soluble intercellular adhesion molecule-1 in MS: Relation to clinical and Gd-MRI activity and to rIFNβ-1b treatment

Multiple Sclerosis

Volumn 4, Issue 3, 1998, Pages 183-187

  Trojano, M ^a   Avolio, C ^a   Ruggieri, M ^a   Defazio, G ^a   Giuliani, F ^a   Paolicelli, D ^a   Livrea, P ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Gadolinium MRI; rIFN 1b; Soluble ICAM 1

Indexed keywords

GADOLINIUM; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON BETA SERINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE;

EID: 0031658820     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245898678909510     Document Type: Article

References (17)

1. Rieckmann P et al. (1995) Soluble forms of intercellular adhesion molecule-1 (ICAM-I) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 60: 9 - 15.
2. Trojano M et al. (1996) Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. Neurology 47: 1535 - 1541.
3. Morrisey SP et al. (1996) Partial inhibition of AT-EAE by an antibody to IGAM-1: clinico-histopathological and MRI studies. J Neuroimmunol 69: 85 - 93.
4. Tsukada N et al. (1993) Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. Ann Neurol 33: 646 - 649.
5. Rieckmann P et al. (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44: 2367 - 2372.
6. Hartung HP et al. (1993) Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 43: 2331 - 2335.
7. Rieckmann P et al. (1997) Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 41: 326 - 333.
8. Jander S, Heidenreich F, Stoll G. (1993) Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases. Neurology 43: 1809 - 1813.
9. Dore-Duffy P et al. (1995) Circulating soluble adhesions proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 37: 55 - 62.
10. Droogan AG et al. (1996) Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. J Neuroimmunol 64: 185 - 191.
11. Calabresi PA et al. (1997) Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with Interferon β-1b. Ann Neurol 41: 669 - 674.
12. Trojano M et al. (1995) Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 58: 300 - 306.
13. Confavreux C et al. (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55: 671 - 676.
14. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocol. Ann Neurol 13: 227 - 231.
15. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444 - 1452.
16. Schumacher GA et al. (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of the experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 122: 552 - 568.
17. Giovannoni G et al. (1997) Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium-enhanced magnetic resonance imaging. Neurology 48: 1557 - 1565.